Suppr超能文献

乳腺癌干细胞作为新型生物标志物。

Breast cancer stem cells as novel biomarkers.

机构信息

Independent Researcher, Bhopal, Madhya Pradesh 462020, India.

Department of Biochemistry, All India Institute of Medical Sciences, Bhopal, Madhya Pradesh 462020, India.

出版信息

Clin Chim Acta. 2024 Apr 15;557:117855. doi: 10.1016/j.cca.2024.117855. Epub 2024 Mar 5.

Abstract

Breast cancer is the most common cancer and the leading cause of mortality worldwide. Despite advancements in detection and treatment, it remains a major cause of cancer-related deaths in women. Breast cancer stem cells (BCSCs) are a crucial group of cells responsible for carcinogenesis, metastasis, medication resistance, and tumor recurrence. Identifying and understanding their molecular pathways is essential for developing effective breast cancer therapy. BCSCs are responsible for tumor genesis, development, metastasis, treatment resistance, and recurrence. Biomarkers are essential tools for identifying high-risk patients, improving diagnostic accuracy, developing follow-up programs, assessing treatment susceptibility, and predicting prognostic outcomes. Stem cell intervention therapy can provide specialized tools for precision therapy. Biomarker analysis in cancer patients is crucial to identify cells associated with disease progression and post-therapeutic relapse. However, negative post-therapeutic impacts can enhance cancer stemness by boosting BCSCs plasticity phenotypes, activating stemness pathways in non-BCSCs, and promoting senescence escape, leading to tumor relapse and metastasis. Despite the advancements in precision medicine, challenges persist in identifying stem cell markers, limiting the number of eligible patients for treatment. The diversity of biomedical research hinders the development of individualization-based preventative, monitoring, and treatment strategies, especially in oncology. Integrating and interpreting clinical and scientific data remains challenging. The development of stem cell-related indicators could significantly improve disease precision, enabling stem cell-targeted therapy and personalized treatment plans, although BCSCs are promising for breast cancer treatment optimization, serving as biomarkers for current therapy modalities. This summary discusses recent advancements in breast cancer stem cell research, including biomarkers, identification methods, molecular mechanisms, and tools for studying their biological origin and lineage development for precision medicine.

摘要

乳腺癌是全球最常见的癌症和主要死因。尽管在检测和治疗方面取得了进展,但它仍然是导致女性癌症相关死亡的主要原因。乳腺癌干细胞(BCSCs)是一组负责癌发生、转移、药物耐药和肿瘤复发的关键细胞。确定和理解它们的分子途径对于开发有效的乳腺癌治疗方法至关重要。BCSCs 负责肿瘤发生、发展、转移、治疗耐药和复发。生物标志物是识别高危患者、提高诊断准确性、开发随访计划、评估治疗敏感性和预测预后结果的重要工具。干细胞干预治疗可以为精准治疗提供专门的工具。对癌症患者进行生物标志物分析对于识别与疾病进展和治疗后复发相关的细胞至关重要。然而,治疗后的负面影响可能会通过增强 BCSCs 的可塑性表型、激活非 BCSCs 中的干性途径以及促进衰老逃逸来增强癌症干性,导致肿瘤复发和转移。尽管精准医学取得了进展,但仍存在识别干细胞标志物的挑战,限制了可接受治疗的患者数量。生物医学研究的多样性阻碍了个体化预防、监测和治疗策略的发展,尤其是在肿瘤学领域。整合和解释临床和科学数据仍然具有挑战性。开发与干细胞相关的指标可以显著提高疾病的精准度,实现针对干细胞的治疗和个性化治疗计划,尽管 BCSCs 是优化乳腺癌治疗的有希望的候选者,可作为当前治疗方式的生物标志物。本文总结了乳腺癌干细胞研究的最新进展,包括生物标志物、鉴定方法、分子机制以及研究其生物学起源和谱系发育的工具,以用于精准医学。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验